OptiNose Inc (NAS:OPTN)

$ 0.6043 -0.1682 (-21.9%) Market Cap: 91.11 Mil Enterprise Value: 150.63 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 75/100

Q3 2024 OptiNose Inc Earnings Call Transcript
22 hours ago

$0.6043 (-21.34%)

Earnings
Q2 2024 OptiNose Inc Earnings Call Transcript
Aug 08, 2024

$0.95 (-9.52%)

Earnings
Q1 2024 OptiNose Inc Earnings Call Transcript
May 14, 2024

$1.13 (-3.42%)

Earnings
Q4 2023 OptiNose Inc Earnings Call Transcript
Mar 07, 2024

$1.72 (-1.71%)

Earnings
Q3 2023 OptiNose Inc Earnings Call Transcript
Nov 09, 2023

$1.22 (-1.61%)

Earnings
Q2 2023 OptiNose Inc Earnings Call Transcript
Aug 10, 2023

$1.24 (+6.90%)

Earnings
Q1 2023 OptiNose Inc Earnings Call Transcript
May 11, 2023

$1.98 (+6.45%)

Earnings
Q4 2022 OptiNose Inc Earnings Call Transcript
Mar 07, 2023

$1.86 (-2.11%)

Earnings
Q3 2022 OptiNose Inc Earnings Call Transcript
Nov 10, 2022

$2.76 (-15.08%)

Earnings
Q2 2022 OptiNose Inc Earnings Call Transcript
Aug 11, 2022

$3.59 (-2.97%)

Earnings
OptiNose Inc To Discuss ReOpen2 Topline Results Call Transcript
Jun 13, 2022
Q1 2022 OptiNose Inc Earnings Call Transcript
May 12, 2022

$1.76 (-5.38%)

Earnings
OptiNose Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Q4 2021 OptiNose Inc Earnings Call Transcript
Mar 08, 2022

$2.57 (-6.55%)

Earnings
OptiNose Inc To Discuss ReOpen1 Topline Results Call Transcript
Mar 07, 2022
Q3 2021 OptiNose Inc Earnings Call Transcript
Nov 16, 2021

$1.59 (-33.47%)

Earnings
Q2 2021 OptiNose Inc Earnings Call Transcript
Aug 11, 2021

$2.35 (-11.65%)

Earnings
Q1 2021 OptiNose Inc Earnings Call Transcript
May 05, 2021

$3.23 (-2.12%)

Earnings
OptiNose Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 04, 2021
Q4 2020 OptiNose Inc Earnings Call Transcript
Mar 03, 2021

$3.81 (-2.81%)

Earnings
Q3 2020 OptiNose Inc Earnings Call Transcript
Nov 05, 2020

$3.95 (+11.42%)

Earnings
Q2 2020 OptiNose Inc Earnings Call Transcript
Aug 04, 2020

$6.42 (+12.43%)

Earnings
OptiNose Inc Annual Shareholders Meeting Transcript
Jun 10, 2020
Q1 2020 OptiNose Inc Earnings Call Transcript
May 07, 2020

$4.4 (+1.62%)

Earnings
Q4 2019 OptiNose Inc Earnings Call Transcript
Mar 05, 2020

$5.67 (-8.10%)

Earnings
Q3 2019 OptiNose Inc Earnings Call Transcript
Nov 12, 2019

$9.25 (-6.09%)

Earnings
OptiNose Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Oct 02, 2019
Q2 2019 OptiNose Inc Earnings Call Transcript
Aug 12, 2019

$5.61 (+8.30%)

Earnings
Q1 2019 OptiNose Inc Earnings Call Transcript
May 09, 2019

$9.25 (-14.27%)

Earnings
Q4 2018 OptiNose Inc Earnings Call Transcript
Mar 06, 2019

$8.1 (-5.81%)

Earnings

OptiNose Inc To Discuss ReOpen1 Topline Results Call Transcript

Mar 07, 2022 / 09:15PM GMT

Release Date Price: $2.75 (+1.10%)

Transcript 10-K8-K

Operator

Good day, and thank you for standing by. Welcome to the ReOpen1 Top Line Results Conference Call. (Operator Instructions)

Please be advised that today's conference is being recorded. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Jonathan Neely, Vice President of Investor Relations. Please go ahead.

Jonathan Neely

OptiNose, Inc. - VP of IR & Business Operations

Good afternoon, and thank you for joining us today as we review the top line results from the XHANCE ReOpen1 Phase III clinical trial. I'm joined today by our CEO, Peter Miller; our President and Chief Operating Officer, Ramy Mahmoud; our Chief Commercial Officer, Vic Clavelli; our Senior Vice President of Clinical Development and Medical Affairs, John Messina; and our CFO, Keith Goldan. During this call, we will refer to slides that can be viewed on our website, optinose.com, in the Investors section.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.